Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company focused on brain-targeted therapeutics, announced that the first patient has been dosed in its Phase IIa clinical trial evaluating ONP-002 for concussion and mild traumatic brain injury at Mackay Hospital in Australia. The milestone, achieved shortly after site activation on March 31, 2026, follows regulatory approval and highlights progress in advancing a first-in-class intranasal neurosteroid designed to address underlying brain injury mechanisms.
ONP-002 is a proprietary intranasal neurosteroid candidate that targets the pathophysiology of concussion and mild traumatic brain injury (mTBI). The company is expanding trial sites and aims to address a large unmet medical need, as there are currently no FDA-approved pharmacological treatments for concussion. The Phase IIa trial is expected to provide key data on safety and efficacy, with U.S. Phase 2b trials planned to follow.
Oragenics' intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. The company is committed to developing innovative therapies for significant unmet needs in neurological care. For more information about Oragenics and its pipeline, visit oragenics.com.
The full press release is available at https://ibn.fm/85CHs. Updates and news about Oragenics are also posted in the company's newsroom at https://ibn.fm/OGEN.
This announcement marks a significant step forward in the development of a potential treatment for concussion, a condition that affects millions of people worldwide each year. With no approved pharmacological therapies, the need for effective treatments is critical. Oragenics' progress in this trial could pave the way for new therapeutic options for patients suffering from mild traumatic brain injury.
